Literature DB >> 9171346

Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants.

R Mazzieri1, L Masiero, L Zanetta, S Monea, M Onisto, S Garbisa, P Mignatti.   

Abstract

The urokinase-type plasminogen activator (uPA) and the matrix-degrading metalloproteinases MMP-2 and MMP-9 (type IV collagenases/gelatinases) have been implicated in a variety of invasive processes, including tumor invasion, metastasis and angiogenesis. MMP-2 and MMP-9 are secreted in the form of inactive zymogens that are activated extracellularly, a fundamental process for the control of their activity. The physiological mechanism(s) of gelatinase activation are still poorly understood; their comprehension may provide tools to control cell invasion. The data reported in this paper show multiple roles of the uPA-plasmin system in the control of gelatinase activity: (i) both gelatinases are associated with the cell surface; binding of uPA and plasmin(ogen) to the cell surface results in gelatinase activation without the action of other metallo- or acid proteinases; (ii) inhibition of uPA or plasminogen binding to the cell surface blocks gelatinase activation; (iii) in soluble phase plasmin degrades both gelatinases; and (iv) gelatinase activation and degradation occur in a dose- and time-dependent manner in the presence of physiological plasminogen and uPA concentrations. Thus, the uPA-plasmin system may represent a physiological mechanism for the control of gelatinase activity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9171346      PMCID: PMC1169833          DOI: 10.1093/emboj/16.9.2319

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  59 in total

Review 1.  Substrate specificities and activation mechanisms of matrix metalloproteinases.

Authors:  H Nagase; Y Ogata; K Suzuki; J J Enghild; G Salvesen
Journal:  Biochem Soc Trans       Date:  1991-08       Impact factor: 5.407

2.  Development of a novel substrate capture immunoassay for the detection of a neutral metalloproteinase capable of degrading basement membrane (type IV) collagen.

Authors:  M P Wacher; H C Krutzsch; L A Liotta; W G Stetler-Stevenson
Journal:  J Immunol Methods       Date:  1990-02-09       Impact factor: 2.303

3.  The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants.

Authors:  N Behrendt; E Rønne; M Ploug; T Petri; D Løber; L S Nielsen; W D Schleuning; F Blasi; E Appella; K Danø
Journal:  J Biol Chem       Date:  1990-04-15       Impact factor: 5.157

4.  SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages.

Authors:  S M Wilhelm; I E Collier; B L Marmer; A Z Eisen; G A Grant; G I Goldberg
Journal:  J Biol Chem       Date:  1989-10-15       Impact factor: 5.157

5.  Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloproteases designated TIMP-2.

Authors:  G I Goldberg; B L Marmer; G A Grant; A Z Eisen; S Wilhelm; C S He
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

6.  Molecular cloning, chromosomal localization, and bacterial expression of a murine macrophage metalloelastase.

Authors:  S D Shapiro; G L Griffin; D J Gilbert; N A Jenkins; N G Copeland; H G Welgus; R M Senior; T J Ley
Journal:  J Biol Chem       Date:  1992-03-05       Impact factor: 5.157

7.  Tissue inhibitor of metalloproteinases-2 inhibits the activation of 72 kDa progelatinase by fibroblast membranes.

Authors:  R V Ward; S J Atkinson; P M Slocombe; A J Docherty; J J Reynolds; G Murphy
Journal:  Biochim Biophys Acta       Date:  1991-08-30

8.  Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin.

Authors:  G I Goldberg; A Strongin; I E Collier; L T Genrich; B L Marmer
Journal:  J Biol Chem       Date:  1992-03-05       Impact factor: 5.157

9.  Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis.

Authors:  A L Roldan; M V Cubellis; M T Masucci; N Behrendt; L R Lund; K Danø; E Appella; F Blasi
Journal:  EMBO J       Date:  1990-02       Impact factor: 11.598

10.  Mouse L cells expressing human prourokinase-type plasminogen activator: effects on extracellular matrix degradation and invasion.

Authors:  J F Cajot; W D Schleuning; R L Medcalf; J Bamat; J Testuz; L Liebermann; B Sordat
Journal:  J Cell Biol       Date:  1989-08       Impact factor: 10.539

View more
  84 in total

Review 1.  Extracellular matrix degradation by metalloproteinases and central nervous system diseases.

Authors:  A Lukes; S Mun-Bryce; M Lukes; G A Rosenberg
Journal:  Mol Neurobiol       Date:  1999-06       Impact factor: 5.590

2.  Analysis of tissue inhibitor of metalloproteinases-2 effect on pro-matrix metalloproteinase-2 activation by membrane-type 1 matrix metalloproteinase using baculovirus/insect-cell expression system.

Authors:  Y Jo; J Yeon; H J Kim; S T Lee
Journal:  Biochem J       Date:  2000-02-01       Impact factor: 3.857

Review 3.  Clinical implications of matrix metalloproteinases.

Authors:  Malay Mandal; Amritlal Mandal; Sudip Das; Tapati Chakraborti; Chakraborti Sajal
Journal:  Mol Cell Biochem       Date:  2003-10       Impact factor: 3.396

4.  Increased PAI-1 in females compared with males is protective for abdominal aortic aneurysm formation in a rodent model.

Authors:  Paul D DiMusto; Guanyi Lu; Abhijit Ghosh; Karen J Roelofs; Gang Su; Yunge Zhao; Christine L Lau; Omar Sadiq; Brendan McEvoy; Adriana Laser; Jose A Diaz; Thomas W Wakefield; Peter K Henke; Jonathan L Eliason; Gilbert R Upchurch
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-02-03       Impact factor: 4.733

5.  Regulation of proteinases during mouse peri-implantation development: urokinase-type plasminogen activator expression and cross talk with matrix metalloproteinase 9.

Authors:  M G Martínez-Hernández; L A Baiza-Gutman; A Castillo-Trápala; D Randall Armant
Journal:  Reproduction       Date:  2010-11-12       Impact factor: 3.906

6.  Urokinase-type plasminogen activator induces BV-2 microglial cell migration through activation of matrix metalloproteinase-9.

Authors:  Sun Mi Shin; Kyu Suk Cho; Min Sik Choi; Sung Hoon Lee; Seol-Heui Han; Young-Sun Kang; Hee Jin Kim; Jae Hoon Cheong; Chan Young Shin; Kwang Ho Ko
Journal:  Neurochem Res       Date:  2010-02-23       Impact factor: 3.996

7.  Proteolytic processing of membrane-type-1 matrix metalloproteinase is associated with gelatinase A activation at the cell surface.

Authors:  K Lehti; J Lohi; H Valtanen; J Keski-Oja
Journal:  Biochem J       Date:  1998-09-01       Impact factor: 3.857

8.  The arthritis severity locus Cia5d is a novel genetic regulator of the invasive properties of synovial fibroblasts.

Authors:  Teresina Laragione; Max Brenner; Adriana Mello; Marc Symons; Pércio S Gulko
Journal:  Arthritis Rheum       Date:  2008-08

9.  Binding of matrix metalloproteinase 9 to fibrin is mediated by amorphous calcium-phosphate.

Authors:  G S Makowski; M L Ramsby
Journal:  Inflammation       Date:  1998-12       Impact factor: 4.092

10.  The membrane form of the DNA repair protein Ku interacts at the cell surface with metalloproteinase 9.

Authors:  Sylvie Monferran; Jenny Paupert; Stéphanie Dauvillier; Bernard Salles; Catherine Muller
Journal:  EMBO J       Date:  2004-09-23       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.